

IX BIBLIOGRAFÍA

Ashcroft FM (2000) Ion channels and disease channelopathies. Academic Press 97-135.

Aposhian HV (1997) Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. *Annu.Rev. Pharmacol.* 37:397-419.

Barbey JT, Pezzullo JC, Soignet (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. *J Clin Oncol.* 21:3609-3615.

Barry D, Nerbonne JM, Morad M, Ebashi S, Trautwein W, Kurachi Y (1996) Myocardial potassium channels: Electrophysiological and molecular diversity. *Annual Reviews Physiology* 58:363-394.

Bezanilla F (2000) The voltage-sensor in voltage-dependent ion channels. *Physiological Reviews* 80:555-592.

Bezanilla F (2005) The voltage-sensor structure in a voltage-gated channel. *Trends in Biochemical Sciences* 30:166-168.

Catterall WA (1993) Structure and function of voltage-gated ion channels. Elsevier Science Publishers 16:500-506.

Chiang CE, Luk HN, Wang TM, and Ding PYA (2002) Prolongation of cardiac repolarization by arsenic trioxide. *Blood* 100:2249-2252.

Cui X, Kobayashi Y, Hayakawa T and Hirano S (2004) Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats. *Toxicological Sciences* 82:478–487.

Drucker R.R (2005) Fisiología médica. Colín 1^a Ed. Editorial Manual Moderno.

Drolet B, Simard C, and Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. *Circulation* 109:26–29.

Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, Wible BA, and Brown AM (2004) Mechanisms of Arsenic-Induced Prolongation of Cardiac Repolarization. *Mol Pharmacol* 66(1): 33–44.

Fozzard HA Spooner MM, Brown AM (1994) Cardiac electrogenesis and the sodium channel. *Ionic Channels in the cardiovascular system, Function and Dysfunction*. Future Publishing Company 81-99.

Gaspar J, Muñoz-Martínez J, García X (1997) Principios generales de la hemodinámica vascular. Células, órganos y sistemas. Aparato cardiovascular. La sangre y sus funciones. SSA, UNAM, CINVESTAV, IMSS, SMCF, FCE. 1^{ra} edición. México. Pag. 77-92.

Guyton AC, Hall JE (2006) Tratado de Fisiología Médica. 11^a edición. Editorial McGraw-Hill Interamericana. México. Pag.115-136

Hamill, O.P., Marty, A., Neher, E (1981) Improved patch clamp techniques for high-resolution current recording from cell and cell-free membrane patches. *Pfluger Arch*. 391:85-100.

Hartzell HC (1996) Overview: Channels and channel proteins. *Molecular physiology and pharmacology of cardiac ion channels and transporters*. Kluwer Academic Publishers 3-15.

Klassen CD, Goodman & Gilman. *The Pharmacological Basis of Therapeutics*. (2002) 9th Edition. McGraw-Hill. USA. Vol. II Chapter 67, PP. 1873-1893.

Hille B (2001) Ionic channels of excitable membrane. 3rd Edition, Sinauer Associates. Publishers Sunderland, Massachusetts. PP. 23-58.

Ho K, Nichols CG, Ledrer WJ, Lytton J, Vassilev PM, Kanazirska MV, Hebert SC (1993) Cloning and expression of an inward rectifying ATP-regulated potassium channel. *Nature Lond* 362:31-38.

Hodgkin AL, Huxley AF (1952) A quantitative description of membrane current and its application to conduction and excitation in nerve. *J. Physiology. Lond* 117:500-544.

Hoshi T, Zagota WN, Aldrich RW (1990) Biophysical and molecular mechanisms of Shaker potassium channel inactivation. *Science*. 250:533-538.

Hoshi T, Zagota WN, Aldrich RW (1991) Two types of inactivation in Shaker K⁺ channels: effects of alterations in the carboxy-terminal region. *Neuron* 7:547-556.

Isenberg G and Klockner U (1982) Calcium-tolerant ventricular myocytes prepared by preincubation in KB-medium. *Pfluegers Arch*. 395:6-18

Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, and Lieberman MW (2000) The MRP2/cMOAT Transporter and Arsenic-Glutathione Complex Formation Are Required for Biliary Excretion of Arsenic. *The Journal of Biological Chemistry* 275(43):33404–33408.

Katchman AN, Koerner J, Tosaka T, Woosley RL and Ebert SN (2006) Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs. *JPET* 316:1098–1106.

Katz AM (2000) Physiology of the heart. Lippincott Williams y Wilkins Phyladelphia, PA 19106 USA 3nd Edition. Raven Press. PP. 10-510.

Kenyon JL and Gibbons WR (1979) 4-Aminopyridine and the early outward current of sheep cardiac Purkinje fibers. Journal of General Physiology 73:139-157.

Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY (1993) Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature Lond 364:802-806.

Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM (2001) Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs Eur Heart J Supplements. 3 (Suppl K): K23–K30.

Lauer B, Niederau C, Kuhl U, Schannwell M, Pauachinger M, Strauer BE (1997) Cardiac Troponin T in Patients With Clinically Suspected Myocarditis. American College of Cardiology 30:1354 –9.

Leslie EM, Haimeur A and Waalkes MP (2004) Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1): evidence that a tri-glutathione conjugate is required. The Journal of Biological Chemistry 279 (31): 32700–32708.

Liu J, Chen H, Miller DS, Saavedra JE, Keefer LK, Johnson DR, Klaassen CD, and Waalkes MP (2001) Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic. Mol Pharmacol 60:302–309.

Lopatin AN, Makhina EN, Nichols CG (1994) Potassium channel block by cytoplasmic polyamines as the mechanism of intrinsic rectification. *Nature* 372:366-369.

Miller WH, Schipper HM, Lee JS, Singer J and Waxman S (2002) Mechanisms of Action of Arsenic Trioxide. *Cancer Research. Review* 62: 3893–3903.

Nattel S, YUE L, Wang Z (1999) Cardiac ultrarapid delayed rectifiers. *Cell Physiology Biochemistry* 9:217-226.

Navas-Acien A, Sharrett RA, Silbergeld EK, Schwartz BS, Nachman KE, Burke TA and Guallar E (2005) Arsenic Exposure and Cardiovascular Disease. A Systematic Review of the Epidemiologic Evidence. *Am J Epidemiol* 162:1037–1049.

Nerbonne JM (2000) Molecular basis of functional voltage-gated K⁺ channel diversity in the mammalian myocardium. *Journal of Physiology* 525:285-298.

Nichols CG, Makhina EN, Pearson WL, Sha Q, Lopatin AN (1996) Inward rectification and implications for cardiac excitability. *Circulation Research* 78:1-7.

Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H and Ohno R (2000) Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia *Ann Intern Med* 133:881-885.

Opie LH (2004) *The Heart: Physiology, from cell to circulation*. Fourth Edition. Lippicott Williams and Wilkins, USA PP.17-43.

Rasmusson RL, Morales MJ, Wang S, Liu S, Campbell DL, Brahmajothi MV, Strauss HC (1998) Inactivation of voltage-gated cardiac K⁺ channels. *Circulation Research* 82:739-750.

Ratnaik RN (2003) Acute and chronic arsenic toxicity. *Postgrad Med J* 79:391–396.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. (2002) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Elsevier Science. 1-44

Rossmann TG, Uddin AN, Burns FJ and Bosland MC (2002) Arsenite Cocarcinogenesis: An Animal Model Derived from Genetic Toxicology Studies. *Environ Health Perspect* 110(5):749–752.

Rust DM, Soignet SL (2001) Risk/benefit profile of arsenic trioxide. *The Oncologist*. 6: 29 – 32.

Rudy Y, Zipes DP, Jalife J (2000) *Cardiac Electrophysiology: From Cell to Bedside*. Ionic mechanism of cardiac electrical activity. Third edition. Saunders Company 257-265.

Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K⁺ current. Differential sensitivity to block by class III antiarrhythmic agents. *The Journal of General Physiology* 96:195-215.

Sanguinetti MC, Jurkiewicz NK, Spooner MM, Brown AM (1994) Delayed Rectifier Potassium Channels of cardiac muscle: Ionic Channels in the

cardiovascular system, Function and Dysfunction. Futura Publishing Company:121-143.

Sanz MA (2006) Treatment of Acute Promyelocytic Leukemia. Session Chair: Bob Löwenberg. Hematology 147-155.

Schlant RC, Silverman ME, Hurst JW, Schlant RC (1994) Anatomía del corazón: el corazón arterias y venas. Interamericana-McGraw-Will Séptima edición 1:17-39.

Schoen A, Beck B, Sharma R and Dubé E (2004) Arsenic toxicity at low doses: epidemiological and mode of action considerations. Toxicology and Applied Pharmacology 198:253– 267.

Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M (2000) Potassium channels: Molecular defects, diseases and therapeutic opportunities. Pharmacological Reviews 52:557-593.

Snyders DJ (1999) Structure and function of cardiac potassium channels. Cardiovascular Research 42:377-390.

Snyders DJ, Zipes DP, Jalife J. (2000) Cardiac Electrophysiology: From Cell to Bedside. Molecular biology of potassium channels. Third edition. Saunders Company 21-31.

Tseng GN, Hoffman BF (1989) Two components of transient outward current in canine ventricular myocytes. Circ. Res. 64:633-647

Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH and Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 97:1514-1516.

Vandenberg CA, Spooner MM, Brown AM (1994) Cardiac inward rectifier potassium channel: Ionic Channels in the cardiovascular system, Function and Dysfunction. Futura Publishing Company 145-167.

Vernhet I, Allain N, Vée ML, Morel F, Guillouzo A, and Fardel O (2003) Blockage of Multidrug Resistance-Associated Proteins Potentiates the Inhibitory Effects of Arsenic Trioxide on CYP1A1 Induction by Polycyclic Aromatic Hydrocarbons. JPET 304:145–155.

Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, and DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukaemia treated with arsenic trioxide. Blood 98:266-271

Yamazaki K, Terada H, Satoh H, Naito K, Takeshita A, Uehara A, Katoh H, Ohnishi K, Hayashi H (2006) Arrhythmogenic Effects of Arsenic Trioxide in Patients With Acute Promyelocytic Leukemia and an Electrophysiological Study in Isolated Guinea Pig Papillary Muscles. Circ J 70:1407–1414.

Zigmunt AC, Gibbons WA (1992) Properties of the calcium activated chloride current in the heart. Journal of General Physiology 391-414.